316 related articles for article (PubMed ID: 18507044)
1. HER3 expression in cutaneous tumors.
Wimmer E; Kraehn-Senftleben G; Issing WJ
Anticancer Res; 2008; 28(2A):973-9. PubMed ID: 18507044
[TBL] [Abstract][Full Text] [Related]
2. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
3. High numbers of human skin cancers express MMP2 and several integrin genes.
Orimoto AM; Neto CF; Pimentel ER; Sanches JA; Sotto MN; Akaishi E; Ruiz IR
J Cutan Pathol; 2008 Mar; 35(3):285-91. PubMed ID: 18251742
[TBL] [Abstract][Full Text] [Related]
4. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
5. Expression of hurpin, a serine proteinase inhibitor, in normal and pathological skin: overexpression and redistribution in psoriasis and cutaneous carcinomas.
Moussali H; Bylaite M; Welss T; Abts HF; Ruzicka T; Walz M
Exp Dermatol; 2005 Jun; 14(6):420-8. PubMed ID: 15885077
[TBL] [Abstract][Full Text] [Related]
6. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
7. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
9. Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?
Woenckhaus C; Giebel J; Failing K; Fenic I; Dittberner T; Poetsch M
J Pathol; 2003 Oct; 201(2):278-87. PubMed ID: 14517845
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
Stoebner PE; Le Gallic L; Berthe ML; Boulle N; Lallemant B; Marque M; Gaspard C; Delfour C; Lavabre-Bertrand T; Martinez J; Meunier L
Exp Dermatol; 2008 Nov; 17(11):908-15. PubMed ID: 18341568
[TBL] [Abstract][Full Text] [Related]
11. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
12. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
13. Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas.
Chan MM; Tahan SR
J Cutan Pathol; 2010 Mar; 37(3):336-43. PubMed ID: 19615036
[TBL] [Abstract][Full Text] [Related]
14. No evidence for c-erbB-2 overexpression in cutaneous melanoma.
Fink-Puches R; Pilarski P; Schmidbauer U; Kerl H; Soyer HP
Anticancer Res; 2001; 21(4A):2793-5. PubMed ID: 11724356
[TBL] [Abstract][Full Text] [Related]
15. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J
Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674
[TBL] [Abstract][Full Text] [Related]
16. Greater expression of TC21/R-ras2 in highly aggressive malignant skin cancer.
Lee JH; Pyon JK; Lee SH; Lee YJ; Kang SG; Kim CH; Kim DW; Nam HS; Park YH; Jeong DJ; Cho MK
Int J Dermatol; 2011 Aug; 50(8):956-60. PubMed ID: 21781067
[TBL] [Abstract][Full Text] [Related]
17. Nestin expression in cutaneous melanomas and melanocytic nevi.
Brychtova S; Fiuraskova M; Hlobilková A; Brychta T; Hirnak J
J Cutan Pathol; 2007 May; 34(5):370-5. PubMed ID: 17448190
[TBL] [Abstract][Full Text] [Related]
18. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
19. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
20. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
Kuźbicki L; Gajo B; Chwirot BW
Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
